Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of BMS-986165 in Active Discoid and/or Subacute Cutaneous Lupus Erythematosus
2020-000071-21Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE) and cutaneous lupus erythematosus (CLE) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percentage change from baseline in CLASI activity (CLASI-A) score. Started Jan 2021; status: active.
02
Drugs
deucravacitinib
03
Conditions
discoid lupus erythematosus (DLE)subacute cutaneous lupus erythematosus (SCLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on 2020-000071-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000071-21.